Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has announced its participation in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on August 14, 2024 at 10:00 a.m. Eastern Time. The event will be webcast live on Acadia's website and archived for approximately one month.
Acadia is a neuroscience company with a 30-year history of developing breakthrough treatments. They have FDA-approved drugs for Parkinson's disease psychosis and Rett syndrome. Their current clinical-stage efforts focus on Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuropsychiatric symptoms in CNS disorders.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) ha annunciato la sua partecipazione a un incontro informale al 44° Convegno annuale sulla crescita di Canaccord Genuity il 14 agosto 2024 alle 10:00 ora orientale. L'evento sarà trasmesso in diretta web sul sito di Acadia e archiviato per circa un mese.
Acadia è un'azienda di neuroscienze con una storia di 30 anni nello sviluppo di trattamenti innovativi. Hanno farmaci approvati dalla FDA per la psicosi da malattia di Parkinson e per la sindrome di Rett. I loro attuali sforzi nella fase clinica si concentrano sulla sindrome di Prader-Willi, sulla psicosi da malattia di Alzheimer e su altri sintomi neuropsichiatrici nei disturbi del sistema nervoso centrale.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) ha anunciado su participación en un chat informal en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity el 14 de agosto de 2024 a las 10:00 a.m. Hora del Este. El evento será transmitido en vivo en el sitio web de Acadia y archivado durante aproximadamente un mes.
Acadia es una empresa de neurociencia con 30 años de historia en el desarrollo de tratamientos innovadores. Tienen medicamentos aprobados por la FDA para la psicosis asociada a la enfermedad de Parkinson y la síndrome de Rett. Sus actuales esfuerzos en fase clínica se centran en la sindrome de Prader-Willi, la psicosis asociada a la enfermedad de Alzheimer y otros síntomas neuropsiquiátricos en trastornos del sistema nervioso central.
아카디아 제약 주식회사(Acadia Pharmaceuticals Inc.)(Nasdaq: ACAD)는 켄카드 제뉴이티 제44회 연례 성장 컨퍼런스에 2024년 8월 14일 오전 10:00(동부 표준시)에 화상 대화에 참여할 것이라고 발표했습니다. 이 행사는 아카디아의 웹사이트에서 생중계되며 약 한 달 동안 아카이브됩니다.
아카디아는 30년의 역사를 가진 신경과학 회사로 혁신적인 치료법을 개발해 왔습니다. 그들은 파킨슨병 정신병과 레트 증후군에 대한 FDA 승인 약물을 보유하고 있습니다. 현재 임상 단계에서 그들의 노력은 프라더-윌리 증후군, 알츠하이머병 정신병, 및 CNS 장애에서의 기타 신경정신증상에 집중되고 있습니다.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) a annoncé sa participation à une discussion informelle lors de la 44e Conférence Annuelle de Croissance de Canaccord Genuity le 14 août 2024 à 10h00, heure de l'Est. L'événement sera diffusé en direct sur le site web d'Acadia et archivé pendant environ un mois.
Acadia est une entreprise de neurosciences avec 30 ans d'expérience dans le développement de traitements innovants. Ils disposent de médicaments approuvés par la FDA pour la psychose de la maladie de Parkinson et le sydrome de Rett. Leurs efforts cliniques actuels se concentrent sur le sydrome de Prader-Willi, la psychose de la maladie d'Alzheimer et d'autres symptômes neuropsychiatriques dans les troubles du système nerveux central.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) hat seine Teilnahme an einem informellen Gespräch auf der 44. jährlichen Wachstumsconference von Canaccord Genuity am 14. August 2024 um 10:00 Uhr Eastern Time bekannt gegeben. Die Veranstaltung wird auf der Website von Acadia live übertragen und für etwa einen Monat archiviert.
Acadia ist ein Unternehmen im Bereich der Neurowissenschaften mit einer 30-jährigen Geschichte in der Entwicklung bahnbrechender Behandlungen. Sie verfügen über von der FDA genehmigte Medikamente für Psychose bei Parkinson-Krankheit und Rett-Syndrom. Ihre aktuellen klinischen Bemühungen konzentrieren sich auf Prader-Willi-Syndrom, Psychose bei Alzheimer-Krankheit und andere neuropsychiatrische Symptome bei Erkrankungen des zentralen Nervensystems.
- None.
- None.
A live webcast of Acadia’s fireside chat will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807578775/en/
Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com
Acadia Pharmaceuticals Inc.
Jessica Tieszen
(858) 261-2950
ir@acadia-pharm.com
Source: Acadia Pharmaceuticals Inc.
FAQ
When is Acadia Pharmaceuticals (ACAD) participating in the Canaccord Genuity conference?
How can investors access Acadia's (ACAD) fireside chat at the Canaccord conference?
What are Acadia Pharmaceuticals' (ACAD) main FDA-approved drugs?
What areas is Acadia Pharmaceuticals (ACAD) currently focusing on in clinical-stage development?
